Increased serum matrix metalloproteinase-9 in neuromyelitis optica: implication of disruption of blood-brain barrier

J Neuroimmunol. 2011 Jul;236(1-2):81-6. doi: 10.1016/j.jneuroim.2011.04.009. Epub 2011 May 31.


Matrix metalloproteinase-9 (MMP-9) plays an important role in some neuroinflammatory diseases through the blood-brain barrier (BBB) disruption. To investigate the pathogenicity of MMP-9 in neuromyelitis optica (NMO), serum and CSF MMP-9 concentrations were measured in 13 NMO and 15 multiple sclerosis (MS) patients and 14 healthy controls, and correlated with clinical and laboratorial parameters. Serum MMP-9 concentrations were significantly higher in NMO than MS and controls, and correlated with EDSS score, CSF/serum albumin ratio, and CSF IL-8 concentrations. Our results indicate that MMP-9, promoted by elevated IL-8 activation, plays a crucial role in the pathogenesis of NMO through the BBB disruption.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Biomarkers / blood
  • Biomarkers / cerebrospinal fluid
  • Blood-Brain Barrier / enzymology*
  • Blood-Brain Barrier / physiopathology*
  • Female
  • Humans
  • Male
  • Matrix Metalloproteinase 9 / blood*
  • Matrix Metalloproteinase 9 / cerebrospinal fluid*
  • Middle Aged
  • Neuromyelitis Optica / cerebrospinal fluid
  • Neuromyelitis Optica / enzymology*
  • Neuromyelitis Optica / physiopathology*
  • Tissue Inhibitor of Metalloproteinase-1 / blood
  • Tissue Inhibitor of Metalloproteinase-1 / cerebrospinal fluid
  • Young Adult


  • Biomarkers
  • Tissue Inhibitor of Metalloproteinase-1
  • Matrix Metalloproteinase 9